Research breakthroughs are around the corner. In 2023, OCRA announced $9.2 million in research initiatives for 2024 — the largest in our history — including awarding 20 grants to scientists at 15 prestigious institutions. Recommended for funding by OCRA’s Scientific Advisory Committee from a competitive evaluation process, these exceptional researchers and their forward-thinking studies will tackle … Continued
An OCRA research team is using Artificial Intelligence (AI) to develop a blood test to potentially detect ovarian cancer, as part of an OCRA-funded study in partnership with Microsoft AI for Good Lab. OCRA grantee Daniel Heller, PhD, lead researcher at The Daniel Heller Lab at Memorial Sloan Kettering Cancer Center discusses this cutting-edge technology … Continued
Snap Summary: OCRA-funded researchers discovered a potential key to reducing chemotherapy resistance, and reducing recurrence rates for the most common type of ovarian cancer. A research team at Magee-Women’s Research Institute, University of Pittsburgh, made a breakthrough in the fight to tackle chemoresistance, a pervasive issue in ovarian cancer treatment. This groundbreaking study was led … Continued
Snap Summary: New findings could help develop better immune therapy for patients with the most common and lethal subtype of ovarian cancer. A recent study co-authored by Dr. Sherry Wu of The University of Queensland, Brisbane, and made possible in part by funding from OCRA, is making inroads toward immunotherapy as a viable option for … Continued
Snap Summary: Research co-funded by OCRA found that foregoing genetic counseling before and after genetic testing does not negatively impact individuals who do not have a pathogenic mutation. Studies have shown that people who might have a hereditary cancer risk often do not get tested. This makes it important to identify needless barriers that may … Continued
Snap Summary: An OCRA-funded study sought to understand why certain ovarian cancer cells resist olaparib treatment, and discovered that introducing a second drug (mifepristone) while targeting certain cells (polyploid giant cancer cells) may offer a solution. In a study published in the journal Science Advances, researchers at MD Anderson Cancer Center set their sights on … Continued
Snap summary: OCRA-funded researchers set out to improve immune response against a known therapeutic target, and provided a glimpse into a world where an ovarian cancer patient’s own immune system can be harnessed to treat and eradicate the disease. Researchers at Roswell Park Comprehensive Cancer Center have made significant gains toward immunotherapy as a viable … Continued
A new study, published in the Journal of Clinical Investigation and funded in part by OCRA, has found that mesothelial cells are a critical factor in ovarian cancer metastasis. High-grade serous ovarian cancer, the most common ovarian cancer subtype, is known to be aggressive, and is associated with the presence of ascites and widespread metastases … Continued
A recent study, funded in part by OCRA, has shed new light on how the most common subtype of ovarian cancer develops and metastasizes, by identifying a key molecule that allows malignancies in the fallopian tube to migrate to the ovaries and continue to grow. High-grade serous ovarian carcinoma (HGSOC) is the most common subtype … Continued
As immunotherapies have seen rising success in treating several other cancers, researchers are hard at work uncovering why immunotherapy for ovarian cancer has, so far, proven ineffective. In a study published in Nature, a research team at Memorial Sloan Kettering Cancer Center set out to identify specific factors that lead to immune evasion in high-grade … Continued
A recent study partly funded by OCRA, and published in the Journal of Clinical Oncology, has shown that frequent aspirin use (defined as more than six times per week for more than six months) is associated with a reduction in ovarian cancer risk. Three members of OCRA’s Scientific Advisory Committee – Dr. Andrew Berchuck (also … Continued
Targeting a specific oncogene associated with the most common type of ovarian cancer may help increase a patient’s immune response to tumors, according to recent findings from researchers at The Wistar Institute and their colleagues at University of Pennsylvania and The University of Colorado Anschutz Medical Campus. An oncogene is a mutated version of a … Continued
Get email updates about research news, action alerts, and ways to join the fight.
A global, Al-powered ecosystem designed to transform gynecologic cancer research—connecting patients, researchers, and clinicians to accelerate breakthroughs.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
